Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:23 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
NCT03978611 · Bristol-Myers Squibb · PHASE1 · terminated · last registry update 2024-07-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business objectives have changed.” | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against LAG3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-30Results posted on the registry: Merck Sharp & Dohme LLC, Favezelimab + Pembrolizumab (NCT02720068)
- 2025-04-22Results posted on the registry: MacroGenics, margetuximab + Retifanlimab (NCT04082364)
- 2025-04-08Also stopped (withdrawn): Merck Sharp & Dohme LLC, Pembrolizumab + Favezelimab (NCT06395090)
- 2025-03-18Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Relatlimab (NCT04623775)
- 2025-02-14Also stopped (terminated): Multiple Myeloma Research Consortium, Elotuzumab, pomalidomide, dexamethasone + Anti-LAG-3 (NCT04150965)
- 2025-02-13Results posted on the registry: Jose Lutzky, MD, Nivolumab + Relatlimab (NCT04552223)
- 2025-01-28Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Nivolumab + Relatlimab (NCT03642067)
- 2024-12-19Phase 3 first posted: Immatics US, Inc., IMA203 + nivolumab plus relatlimab (NCT06743126)
- 2024-12-18Results posted on the registry: Immutep S.A.S., eftilagimod alpha + pembrolizumab (KEYTRUDA®) (NCT03625323)
- 2024-12-10Phase 3 first posted: Immutep S.A.S., eftilagimod alfa + carboplatin plus paclitaxel (NCT06726265)
- 2024-10-08Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Relatlimab (NCT04567615)
- 2024-10-03Phase 3 first posted: Linnaeus Therapeutics, Inc., LNS8801 + Pembrolizumab (NCT06624644)
- 2024-08-20Phase 3 first posted: Bristol-Myers Squibb, Nivolumab + Relatlimab (NCT06561386)
- 2024-07-26Also stopped (withdrawn): Regeneron Pharmaceuticals, cemiplimab + fianlimab (NCT06384820)
- 2024-07-24Results posted on the registry: National Institute of Neurological Disorders and Stroke (NINDS), Nivolumab + BMS-986016 (NCT03493932)
- 2024-05-06Also stopped (withdrawn): National Cancer Institute (NCI), Nivolumab + Relatlimab (NCT06400264)
- 2024-04-05Results posted on the registry: M.D. Anderson Cancer Center, Ipilimumab + Nivolumab (NCT02519322)
- 2024-04-04Results posted on the registry: Celgene, JCAR017 + Durvalumab (NCT03310619)
- 2024-02-16Phase 3 first posted: Replimune, Inc., Vusolimogene Oderparepvec + Nivolumab (NCT06264180)
- 2024-02-07Phase 3 first posted: Regeneron Pharmaceuticals, fianlimab + cemiplimab (NCT06246916)
- 2024-01-18Results posted on the registry: Novartis Pharmaceuticals, PDR001 + LAG525 (NCT03484923)
- 2023-12-20Results posted on the registry: MacroGenics, Enoblituzumab + Retifanlimab (NCT04634825)
- 2023-12-20Also stopped (terminated): MacroGenics, Enoblituzumab + Retifanlimab (NCT04634825)
- 2023-11-01Phase 3 first posted: Immunocore Ltd, Brenetafusp + Nivolumab (NCT06112314)
- 2023-08-14Phase 3 first posted: National Cancer Institute (NCI), Nivolumab + Relatlimab (NCT05987241)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision